therapeutic action: reduction of unnecessary antifungal exposure

Reevaluating the Value of (1,3)-β-D-Glucan for the Diagnosis of Intra-Abdominal Candidiasis in Critically Ill Patients: Current Evidence and Future Directions

This review examines how a fungal biomarker called beta-D-glucan (BDG) can help doctors diagnose yeast infections in the abdomens of critically ill patients. While BDG tests in the blood are available, they give many false positives. Testing BDG directly in fluid from the abdomen appears more accurate, especially when combined with blood tests. However, more research is needed before hospitals widely adopt this approach in daily practice.

Read More »
Scroll to Top